BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.61−0.07 (-0.91%)
Close on Nov 13, 2026Market cap $1.94BP/E –Yield –
BioCryst Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
BioCryst Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 97.9%. For fiscal 2025 it was 97.8%, against 97.3% the year before. The highest annual figure on record is 100.0% in fiscal 2014.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 97.8% | +0.5 |
| FY2024 | Dec 31, 2024 | 97.3% | −1.4 |
| FY2023 | Dec 31, 2023 | 98.6% | +1.0 |
| FY2022 | Dec 31, 2022 | 97.6% | +2.2 |
| FY2021 | Dec 31, 2021 | 95.4% | +4.1 |
| FY2020 | Dec 31, 2020 | 91.3% | −1.1 |
| FY2019 | Dec 31, 2019 | 92.4% | −3.1 |
| FY2017 | Dec 31, 2017 | 95.5% | +4.2 |
| FY2016 | Dec 31, 2016 | 91.3% | −5.9 |
| FY2015 | Dec 31, 2015 | 97.2% | −2.8 |
| FY2014 | Dec 31, 2014 | 100.0% | +0.1 |
| FY2010 | Dec 31, 2010 | 99.9% | +6.0 |
| FY2009 | Dec 31, 2009 | 93.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 99.1% | +0.5 |
| Q2 FY2026 | Jun 30, 2026 | 98.2% | −0.0 |
| Q1 FY2026 | Mar 31, 2026 | 96.6% | −0.3 |
| Q4 FY2025 | Dec 31, 2025 | 97.7% | +2.3 |
| Q3 FY2025 | Sep 30, 2025 | 98.6% | +1.4 |
| Q2 FY2025 | Jun 30, 2025 | 98.3% | −0.2 |
| Q1 FY2025 | Mar 31, 2025 | 96.9% | −1.8 |
| Q4 FY2024 | Dec 31, 2024 | 95.4% | −3.0 |
| Q3 FY2024 | Sep 30, 2024 | 97.3% | −1.5 |
| Q2 FY2024 | Jun 30, 2024 | 98.4% | −0.5 |
| Q1 FY2024 | Mar 31, 2024 | 98.6% | −0.0 |
| Q4 FY2023 | Dec 31, 2023 | 98.3% | +1.3 |
| Q3 FY2023 | Sep 30, 2023 | 98.7% | +3.4 |
| Q2 FY2023 | Jun 30, 2023 | 98.9% | −0.7 |
| Q1 FY2023 | Mar 31, 2023 | 98.6% | −0.9 |
| Q4 FY2022 | Dec 31, 2022 | 97.0% | −2.1 |
| Q3 FY2022 | Sep 30, 2022 | 95.3% | −3.2 |
| Q2 FY2022 | Jun 30, 2022 | 99.6% | +0.2 |
| Q1 FY2022 | Mar 31, 2022 | 99.5% | +30.6 |
| Q4 FY2021 | Dec 31, 2021 | 99.1% | −0.1 |
| Q3 FY2021 | Sep 30, 2021 | 98.6% | +23.4 |
| Q2 FY2021 | Jun 30, 2021 | 99.4% | −0.6 |
| Q1 FY2021 | Mar 31, 2021 | 68.9% | −31.1 |
| Q4 FY2020 | Dec 31, 2020 | 99.2% | +5.0 |
| Q3 FY2020 | Sep 30, 2020 | 75.1% | −24.9 |
| Q2 FY2020 | Jun 30, 2020 | 100.0% | +0.0 |
| Q1 FY2020 | Mar 31, 2020 | 100.0% | +23.8 |
| Q4 FY2019 | Dec 31, 2019 | 94.1% | −5.9 |
| Q3 FY2019 | Sep 30, 2019 | 100.0% | +13.0 |
| Q2 FY2019 | Jun 30, 2019 | 100.0% | – |
| Q1 FY2019 | Mar 31, 2019 | 76.2% | – |
| Q4 FY2017 | Dec 31, 2017 | 100.0% | – |
| Q3 FY2017 | Sep 30, 2017 | 87.0% | – |
See a number that looks wrong?